Oncolytics Biotech announced positive results regarding the percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial (REO 021) in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of Reolysin in combination with carboplatin and paclitaxel. The study enrolled patients with metastatic or recurrent squamous cell carcinoma of the lung. The primary endpoint of the study is objective tumor response rates.

The percent best overall tumour changes between pre–treatment and up to six treatment cycles were examined. Nineteen (95%) of the twenty evaluable patients exhibited overall tumour shrinkage, (mean [20 patients]; 33.7% shrinkage). To date, Oncolytics has observed nine partial responses (PR), nine stable disease (SD), and three progressive disease (PD) by RECIST criteria for a disease control rate (complete response + PR + SD) of 86%. The study continues to enroll patients.

Reolysin is a formulation of the human reovirus designed to replicate specifically in tumor cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two-thirds of all human cancers.

For more information call (403) 670-7377 or visit www.oncolyticsbiotech.com